It must be clearly stated that retatrutide has no UK marketing authorisation and therefore has no approved SmPC specifying diluent, volume, concentration, or technique
Retatrutide, like other drugs in the GLP-1 class, crosses the blood-brain barrier and influences dopamine signalling in the nucleus accumbens, the brains primary reward centre
[6] Alcohol and beta blockers [edit] Alcohol, more precisely ethanol, is a colorless flammable liquid that is the intoxicating agent in fermented and distilled liquors
Related reproductive-biology effects of NNMT inhibition are also under investigation, with some studies noting effects on embryo implantation in models
CagriSema (the combination) was submitted for FDA approval in December 2025, but cagrilintide on its own is earlier in the process